MedAssets (MDAS) - FREE Research Report

Garner Charles O who is Chief Financial Officer at MedAssets sold 15,207 shares at $20.83 on Jan. 16, 2014. Following this transaction, the Chief Financial Officer owned 5,069 shares meaning that the stake was reduced by 75% with the 15,207-share transaction.

The shares most recently traded at $21.77, up $0.94, or 4.3% since the insider transaction. Historical insider transactions for MedAssets go as follows:

  • 4-Week # shares sold: 13,000
  • 12-Week # shares sold: 225,000
  • 24-Week # shares sold: 296,305

The average volume for MedAssets has been 578,600 shares per day over the past 30 days. MedAssets has a market cap of $1.3 billion and is part of the technology sector and computer software & services industry. Shares are up 10.74% year-to-date as of the close of trading on Thursday.

MedAssets, Inc., a financial and performance improvement company, provides technology-enabled products and services for hospitals, health systems, and other ancillary healthcare providers in the United States. The company has a P/E ratio of 301.6. Currently there are 11 analysts that rate MedAssets a buy, 1 analyst rates it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MDAS - FREE

TheStreet Quant Ratings rates MedAssets as a hold. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, increase in net income and revenue growth. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk, disappointing return on equity and weak operating cash flow. Get the full MedAssets Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Illumina Lights the Way for Biotechs

Illumina Lights the Way for Biotechs

European Pharma Companies Slip on MS Pricing Probe

Biogen Stock Climbs After Goldman Adds to its 'Conviction Buy' List

Pfizer's Poor Earnings Feed the Allergan Tie-Up Fire